- Endostatin
[
thumb|right|Endostatin_monomer,_basic_amino_acid_residues_shown_in_red_[http://www.pdb.org/pdb/explore/explore.do?structureId=1KOE 1KOE] ] Endostatin is a naturally-occurring 20-kDa C-terminal fragment derived fromtype XVIII collagen . It is reported to serve as ananti-angiogenic agent, similar toangiostatin andthrombospondin Endostatin is a angiogenesis inhibitor. Endostatin is a broad spectrum angiogenesis inhibitor and may interfere with the pro-angiogenic action of growth factors such as
basic fibroblast growth factor (bFGF/FGF-2) andvascular endothelial growth factor (VEGF). [cite journal | author=Folkman, J. | title=Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action | journal=Exp. Cell. Res.| year=2006 | volume=312 | part=2 | pages=594–607 | url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16376330&query_hl=23&itool=pubmed_docsum | doi=10.1016/j.yexcr.2005.11.015]Research
Endostatin is currently being studied as part of
cancer research .Phase I
In a Phase I clinical trial of Endostatin of the 19 patients treated, 12 were switched out of the trial by their physicians due to continued progression of their disease. [cite press release | title=Boston hospitals report early results of Endostatin clinical trial | publisher=Dana-Farber Cancer Institute | date=November 2000 | accessdate=2006-07-12 | url=http://www.dfci.harvard.edu/abo/news/pressarchive/110900.asp]
Two patients continued to be treated, and the remaining patients withdrew on their own.
The trial, designed primarily to demonstrate safety, indeed showed that the drug was safe and well-tolerated.
Phase II
In a Phase II clinical trial of Endostatin forty two patients with pancreatic endocrine tumors or
carcinoid tumors were treated. [cite journal | author=Kulke M H et al | title=Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors | journal= J. Clin. Oncol.| year=2006 | volume=24 | part=22 | pages=3555–3561 | url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16877721&query_hl=1&itool=pubmed_docsum | doi=10.1200/JCO.2006.05.6762 | pmid=16877721] Of the 40 patients which could be evaluated for a radiologic response, none experienced partial response to therapy, as defined byWorld Health Organization criteria.The conclusion from the trial was that "Treatment with Endostatin did not result in significant tumor regression in patients with advanced neuroendocrine tumors."
References
External links
*
* http://video.google.ca/videoplay?docid=6419681728654132172&q=frontiers+of+medicine+duration%3Along
* [http://www.pbs.org/wgbh/nova/cancer/program.html PBS' Nova program explores Endostatin in 2001]
Wikimedia Foundation. 2010.